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Abstract This study was designed to investigate the function-
al heterogeneity of human Th17 and how their plasticity shapes
the nature of immune cell responses to inflammation and
autoimmune diseases, such as systemic lupus erythematosus
(SLE). We evaluated functional Th17 cell subsets based on the
profile of cytokine production in peripheral blood (PB), bone
marrow aspirates (BM) and lymph node biopsies (LN) from
healthy individuals (n=35) and PB from SLE patients (n=34).
Data were analysed by an automated method for merging and
calculation of flow cytometric data, allowing us to identify
eight Th17 subpopulations. Normal BM presented lower
frequencies of Th17 (p=0.006 and p=0.05) and lower amount
of IL-17 per cell (p=0.03 and p=0.02), compared to normal
PB and LN biopsies. In the latter tissues were found increased
proportions of Th17 producing TNF-α or TNF-α/IL-2 or
IFN-γ/TNF-α/IL-2, while in BM, Th17 producing other
cytokines than IL-17 was clearly decreased. In SLE patients,
the frequency of Th17 was higher than in control, but the
levels of IL-17 per cell were significantly reduced (p<0.05).
Among the eight generated subpopulations, despite the great
functional heterogeneity of Th17 in SLE, a significant low
proportion of Th17 producing TNF-α was found in inactive
SLE, while active SLE showed a high proportion producing
only IL-17. Our findings support the idea that the functional
heterogeneity of Th17 cells could depend on the cytokine
microenvironment, which is distinct in normal BM as well as
in active SLE, probably due to a Th1/Th2 imbalance
previously reported by our group.
Keywords Bone marrow. Lymph node biopsies
Pro-inflammatory cytokines . Systemic lupus erythematosus .
Th17
Introduction
Although it has been known for over 10 years that activated
CD4+ T cells produce IL-17, the existence of a third subset of
CD4+ effector T helper cells, named Th17 cells, has only
recently been identified as an independent Tcell lineage, distinct
from classical Th1 and Th2 cells [1–3]. Nevertheless, a
common developmental origin between human Th17 and
Th1 cells has been described in various studies [4–6].
Accordingly, human Th17 clones appear to express IL-
12Rβ2 in addition to IL-23R, and the transcription factor T-
bet in addition to RORγt, as well a remarkable proportion of
human Th17 cells, produces both IL-17A and IFN-γ, or
human Th17 clones can be induced to produce IFN-γ and up-
regulate T-bet expression when cultured in the presence of IL-
12 [7]. This close relationship between Th1 and Th17 cells is
also marked in their capacity to cause T-cell-mediated inflam-
mation and autoimmune disease. In fact, Th17 cells have been
found to have a pathogenic role in several autoimmune
disorders, including experimental autoimmune encephalomyeli-
tis [8], rheumatoid arthritis [9, 10], inflammatory bowel disease
[11], systemic sclerosis [12] and systemic lupus erythematosus
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(SLE) [13, 14], which were previously thought to be mainly
caused by Th1 responses. Interestingly, new studies show
Th17 cells as more potent than Th1 cells in inducing disease
[15], linking the cytokine IL-17 in coordinating tissue
inflammation via the up-regulation of additional pro-
inflammatory and neutrophil-recruiting cytokines and chemo-
kines, suggesting a pro-inflammatory role in these conditions.
Moreover, in Crohn's disease, the existence of a remarkable
number of double positive IFNγ+/IL17+ T cells, named Th17/
Th1 cells, as well as the possibility to generate Th17/Th1
clones was reported [16]. These latter observations further
support the concept that both Th1 and Th17 cells could
contribute to the maintenance of inflammation in such
disorders via the production of IFNγ and IL-17. However,
whether human autoimmune disorders, including SLE, are
prevalently Th1-mediated or Th17-mediated and how they
might cooperate with one another to perpetuate the inflamma-
tory response are still unclear.
In the present study, we determined the relative
frequency of Th17 cells (through their expression of IL-
17) in peripheral blood samples (PB), bone marrow
aspirates (BM) and lymph node biopsies (LN), simulta-
neously quantifying the frequency of these cells producing
IL-2, TNF-α and IFN-γ. Using an automated method of
integration of flow cytometric data from several multicolour
stains of the same cell sample into a single multicolour
staining data file [17], we described the functional
heterogeneity of human Th17 cells, identifying eight
different Th17 cell subpopulations.
Considering the well-defined role played by cytokines in
the immune deregulation observed in autoimmune diseases,
we compared the distribution of the eight identified Th17
subpopulations in a group of SLE patients and age-matched
healthy control subjects, suggesting that their particular
functional behaviour may differ according to the microen-
vironment condition and participate dynamically in auto-
immune response.
Taken together, our data shed new light on the nature of
human Th17 cells and their close association with Th1
cells, strengthening the relevance of knowing how their




We recruited 10 bone marrow aspirate samples (70%
female, mean age ± SD: 58.3±20.1 years), 15 peripheral
blood samples (73% female, mean age ± SD: 33.8±
9.8 years) and 10 lymph node biopsies (50% female, mean
age ± SD: 48±16.1 years) from healthy individuals at the
Histocompatibility Center of Coimbra; all were free from
autoimmune disease and active infection and were not
undergoing treatment with immunomodulatory drugs for
any known condition. Pregnancy and age below 18 were
exclusion criteria for participation. Bone marrow aspirate
and peripheral blood samples were collected from healthy
donors, while lymph node biopsies were collected from
healthy donor victims of traffic accidents, and organs were
received at the Histocompatibility Center of Coimbra to
perform histocompatibility testing.
Samples from both controls and patients were sent to the
laboratory, identified with a code number, blinding the
laboratory to the disease status. The study protocol was
approved by a local ethics committee, and all participants
gave their signed informed consent.
Patients
We recruited patients fulfilling the 1997 American College
of Rheumatology classification criteria for SLE [18]
followed at the Rheumatology Service of the University
Hospitals of Coimbra, Portugal. After assessing disease
activity at the time of evaluation according to the SLE
Disease Activity Index (SLEDAI, 2000) [19, 20], the PB
samples from the 34 SLE patients were divided in two
groups, one with active (SLEDAI≥5; n=15 comprising
86.7% female, mean age 32±11 years) and the other with
inactive (SLEDAI<5; n=19 comprising 89.5% female,
mean age 34±9 years) SLE [21]. The patient's active
medication at the time of evaluation was recorded. The
clinical features of SLE patients are presented in Table 1.






Mean SLEDAI scores 10.3±3.53 2.7±1.52
Mean time since diagnosis 9±5 9±5
Lupus nephritis 66.7% 52.6%
Neurolupus NF 20%
Lupus arthritis 93.3% 68.4%
Haematological involvement 93.3% 84.2%





NF not found, n sample investigated
aMean daily dose 18.2 and 5.3 mg
bMicofenolate mofetil, azatioprine or cyclosporine
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Immunofluorescent staining of peripheral Th17 subsets
after in vitro stimulation with PMA/ionomycin
in the presence of Brefeldin A
We diluted 500 μL of each sample L/L (vol/vol) in RPMI-
1640 medium (Gibco; Paisley, Scotland, UK), supplemented
with 2-mML-glutamine. We added 50 ng/mL of phorbol 12-
myristate 13-acetate (PMA; Sigma, Saint Louis, MO, USA),
1 μg/mL of ionomycin (Boehringer Mannheim, Germany)
and 10 μg/mL of Brefeldin A (Golgi plug-Sigma, Saint
Louis, MO, USA) and incubated for 4 h at 37°C in a
humidified incubator with 5% CO2 concentration.
Each cultured sample was aliquoted and stained in three
different tubes (200 μL/tube) using an intracytoplasmatic
permeabilization and staining protocol in order to separately
analyse the intracellular expression of IL-2, TNF-α and IFN-γ
in IL-17-positive T cell subpopulations, within the CD4+ T
cell subset. All cell aliquots were stained with anti-IL-17 PE
(clone 41802; R&D Systems, Europe) and separately with
anti-IL-2 FITC (clone MQ1-17H12; BD Pharmingen, San
Diego, CA, USA), anti-TNF-α FITC (clone MAb11; BD
Pharmingen, San Diego, C.A., USA) and anti-IFN-γ FITC
(clone 4S.B3; BD Pharmingen, San Diego, CA, USA)
according to the manufacturer's instructions for fixation and
permeabilization. These monoclonal antibodies (MAbs) were
added to each tube after staining cells for surface expression
of MAbs directed against T lymphocytes subsets—anti-CD3-
PerCP (clone SK7; BD, San Jose, CA, USA) and anti-CD8
APC (clone SK1; BD, San Jose, CA, USA). Among positive
CD3 cells, CD4+ T cells were identified after exclusion of
the γδ-T cell subset according to their higher reactivity with
anti-CD3 monoclonal antibody and typical light scatter. The
election of CD8 instead of CD4 was made concerning the
down-regulation of the CD4 co-receptor after in vitro
stimulation, which is a fact that did not potentially influence
the merging/calculating procedure since, in our study, five
parameters were measured in common—forward light scatter
(FSC), side light scatter (SSC), IL-17 PE, CD3 PerCP and
CD8 APC—given a great security in the calculation of all
the other parameters (IL-2 FITC, TNF-α FITC and IFN-γ
FITC) in three separated four-colour staining of the same cell
sample.
Flow cytometry data acquisition and analysis
Data acquisition was performed in two consecutive steps in
FACSCalibur flow cytometer (BDB, San Jose, CA)
equipped with an argon ion laser and a red diode laser. In
the first step, 2×104 events/test, corresponding to all
nucleated cells present in the sample, were collected. To
improve the sensitivity of the analysis of T cell subsets
present at low frequencies in the different tissue samples, in
the second step, information on CD3+ cells and typical
light scatter contained on a minimum of 3×105 events from
the total sample cellularity was specifically stored through
an electronic live gate. To identify the different T cell
subsets and evaluate cytokine production, we used the
Infinicyt™ software program (Cytognos, Spain). Results
illustrate the percentage of positive cells within each cell
subset or/and their mean fluorescence intensity (MFI).
Merging of flow cytometry data files and estimation
of simultaneous cytokine production in a single file
As shown in Fig. 1, cytokine production was measured in a
single multicolour data file obtained after merging the
original four-colour-staining (six-parameter) data files from
each sample using the Infinicyt™ software program
(Cytognos, Spain) [17]. The basic concepts behind such
strategies require (1) merging of different data files
corresponding to distinct aliquots of a sample, (2) virtual
correction of differences between corresponding cell pop-
ulations present in different aliquots of the same sample and
(3) calculation of immunophenotypic data measured in one
sample aliquot to the corresponding/similar cells measured
in the other aliquots of the same sample. In this sense, it
required the inclusion of backbone reagents, such as anti-
IL-17, -CD8 and -CD3, aimed at the identification of the
cell population of interest—Th17 cells—in all MAb
combinations to increase the reproducibility of the gating
strategy used to select specifically these cell populations in
a sample for the evaluation of their overall cytokine
production (IL-2, TNF-α, INF-γ and IL-17). This strategy
required strict supervision by an experienced operator since
automated adjustment of gates between different data files
may result in inappropriate detection of specific cell
populations.
Sequential merging of all data files from several multi-
colour staining of the same cell sample was performed, and
the calculation function of the Infinicyt™ software was
based on nearest-neighbour statistical tools. Accordingly, in
our study, five parameters were measured in common—
forward light scatter (FSC), side light scatter (SSC), IL-17
PE, CD3 PerCP and CD8 APC—in three separated four-
colour stainings of the same cell sample; all other
parameters (IL-2 FITC, TNF-α FITC and IFN-γ FITC)
were measured only for that subset of cellular events
corresponding to the specific three-colour staining.
Briefly, for each event, a vector in a three-dimensional
space was built-up based on the data measured for the five
common parameters (FSC, SSC, IL-17 PE, CD3 PerCP
and CD8 APC). Then, the nearest neighbour for each
individual event in a data file/sample aliquot was
calculated as that event in another file/aliquot showing
the shortest distance to it in the three-dimensional space
generated by those parameters measured in common in
Clin Rheumatol
both data files/sample aliquots. Then, for each individual
event in a data file, those values obtained for each of the
closest events in the other data files were assigned for each
of those parameters not actually measured in the former
event.
Statistical analysis
Data were analysed using the non-parametric Mann–
Whitney U test. Results were expressed as mean ± SD
and median. All statistical analyses were performed using
SPSS (SPSS Inc., Chicago, USA), and differences were
considered statistically significant when the p value was
less than 0.05.
Results
Frequency of human Th17 cells in different samples
from healthy individuals
As shown in Table 2, the frequency of Th17 among CD4 T
cells in the BM from healthy individuals was significantly
lower than that found in control PB (p=0.006) and LN
samples (p=0.02). The amount of IL-17 produced at single
cell level (mean fluorescent intensity—MFI) was also
markedly decreased in the BM, when compared to PB (p=
0.03) and LN (p=0.02) samples, with the amount of IL-17
being significantly higher in LN (p=0.003) than in PB
(Table 2).
Fig. 1 Bivariate dot plot histograms illustrating the intracellular
expression of IL-17, IL-2, TNF-α and IFN-γ in Th17 cells after the
merging and calculation processes performed on a set of three original
four-color-staining data files corresponding to three aliquots of a
representative PB sample from a ASLE patient, according to five
common parameters—forward light scatter (FSC), side light scatter
(SSC), IL-17 PE, CD3 PerCP and CD8 APC—and stained separately
with IL-2, TNF-α and IFN-γ. Firstly, a gate was set in the whole
merged/calculated data file (e.g., for both actually measured and
calculated events) to define T cells; this gate (CD3 gate) was set in
FSC versus SSC and SSC versus CD3 bivariate dot plot histograms.
In addition, two-dimensional dot-plot representations, corresponding
to combinations of antibodies (IL2, TNF-α, INF-γ) conjugated with
the same fluorochrome (FITC) but not obtained by direct staining of
cells, were generated prior a “P1 gate” to the identification of
“calculated Th17 cells” (a). Among the latter, eight “calculated Th17
subpopulations” were identified combining the three FITC-conjugated
Mab (b–d)
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Functional characterization of human Th17 cells in normal
tissues using an automated flow cytometric method
To further our investigation of the functional activity of
Th17 cells in different tissues in healthy individuals, we
studied the percentage of cells producing different combi-
nations of pro-inflammatory cytokines.
As shown in Fig. 1, we identified eight distinct Th17 cell
subpopulations in healthy subjects, according to their
pattern of cytokine expression (TNF-α, IL-2 and INF-γ),
using an automated flow cytometric method for merging
and calculation of data files.
We found that the majority of normal BMTh17 cells did not
produce type 1 cytokines, resulting in a large subpopulation of
cells showing isolated IL-17 expression (Fig. 2). In contrast, in
both PB and LN samples, clearly distinct subpopulations of
Th17 cells producing different cytokine combinations were
identified with a consequent decrease in the frequency of the
subpopulation producing isolated IL-17 (p=0.02 and p=
0.003, respectively), a difference which was particularly
marked in LN Th17 cells (Fig. 2). The proportion of Th17
cell subpopulation simultaneously producing all studied
cytokines was significantly higher in both peripheral tissues
(PB: p=0.02; LN: p=0.006), especially in LN compared to
BM. The Th17 cell subpopulation simultaneously producing
TNF-α and IL-2 was significantly more represented in LN
than in PB or BM (LN versus BM: p=0.003; LN versus PB:
p=0.005; PB versus BM: p=0.02). Those Th17 cells
producing only TNF-α were also significantly increased in
PB (PB versus BM: p=0.003; PB versus LN: p=0.002) but
markedly decreased in LN when compared to BM (p=0.04),
and Th17 cells producing only IFN-γ were poorly repre-
sented in both peripheral tissue comparatively to BM (PB: p=
0.02 and LN: p=0.003) (Fig. 2).
Frequency of human Th17 cells in peripheral blood in SLE
patients
We found a trend for a higher frequency of Th17 among
CD4 T cells in both active and inactive SLE, but did not
Table 2 Frequency of human Th17 in normal tissues and in PB from SLE patients
Th17 BM PB LN ASLE ISLE
Percent of Th17 cells from
total CD4+ T cells
0.6±0.2 (0.5)* 1.6±0.7 (1.4) 1.6±0.7 (1.5) 1.9±0.9 (1.9) 2.0±1.2 (1.7)
MFI 63.9±25.5 (61.2)** 90.0±20.2 (85.0)# 157.4±50.9 (179.0) 65.8±16.7 (63.9)¶ 62.8±20.7 (60.3)§
Results are expressed as mean ± standard deviation (median). Statistically significant differences were considered when p<0.05 (Mann–
Whitney U test): *p=0.006, **p=0.03 BM versus PB; *p=0.05, **p=0.02 BM versus LN; # p=0.003 PB versus LN; ¶ p=0.006 ASLE versus
PB; § p=0.003 ISLE versus PB
MFI mean fluorescence intensity of positive cells, PB peripheral blood, BM bone marrow, LN lymph node biopsies, ASLE active disease, ISLE
inactive disease
Fig. 2 Frequency of multiple subsets of human Th17 cells in BM, PB
and LN from healthy subjects, according to the production of IL-2, IL-
17, TNF-α and IFN-γ, after in vitro stimulation with PMA/ionomycin
in the presence of Brefeldin A. Data were analysed by an automated
flow cytometric method based in merging file calculation, using
Infinicyt software. BM bone marrow aspirates, PB peripheral blood,
LN lymph node biopsies. Statistically significant differences (p<0.05)
when compared: *BM versus PB and #PB versus LN
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reach statistical significance (Table 2). No differences were
observed in the frequency of Th17 cells between active
SLE and inactive SLE groups. However, analysis of the
amount of IL-17 produced at single cell level (MFI) showed
a significant decreased expression of IL-17 in Th17 cells of
both SLE groups compared to normal controls (ASLE: p=
0.006; ISLE: p=0.003) (Table 2).
Functional characterization of human PB Th17 cells in SLE
patients using an automated flow cytometric method
Since current evidence suggests that there is an increased
expression of IL-17 in patients with a variety of autoim-
mune diseases and a possible developmental relationship
between the Th17 and Th1 phenotypes, we compared the
pattern of distribution of the eight different pro-
inflammatory cytokine-producing Th17 cell subpopulations
in PB samples from SLE and normal controls. Despite the
Th17 cell heterogeneity observed in PB from SLE patients,
the pattern of distribution of the different cytokine-
producing Th17 cell subpopulations observed was relatively
similar to normal subjects (Fig. 3); however, a significant
decrease in the Th17 cell subpopulations producing only
TNF-α and IFN-γ plus IL-2 was found in inactive SLE
patients compared to normal controls (p=0.03) and to
active SLE groups (p=0.02), respectively (Fig. 3). Inter-
estingly, we observed a higher proportion of Th17 cells
producing IL-17 alone in active SLE patients compara-
tively to the other studied groups but as it occurs for other
subpopulations, without significant differences between
groups (Fig. 3).
Discussion
In this study, we have applied a novel software program to
map out the functional phenotype of Th17 cells according
to their pro-inflammatory cytokine production profile,
either in normal tissues or peripheral blood from SLE
patient, to clarify the relevance of those different microen-
vironment conditions in Th17-cell differentiation.
Data published in the past few years suggest the
existence of a novel subset of Th effectors that are distinct
from the classic Th1 and Th2 and that have been named
Th17 because of their ability to produce IL-17. Identified
by IL-17 production, we showed in Table 2 that a clear
decreased proportion of the Th17 cell population was
observed in normal BM as compared to both normal
peripheral tissues (PB and LN), with no significant differ-
ences between the latter groups. When we analysed the
amount of IL-17 expressed at the single-cell level, we
observed a significant increase in both normal peripheral
tissues, particularly in LN (Table 2).
As measured by other studies [16, 22, 23], a remarkable
proportion of Th17 cells also shares the ability to produce
IFN-γ. These cells, producing both IL-17 and IFN-γ, are
usually named Th17/Th1. This new subset of IFN-γ-
producing Th17 cells sharing features with both Th1 and
Th17 challenged us to evaluate other pro-inflammatory
cytokines that could raise new issues on the Th17
developmental and/or functional relationship with Th1 or
even clarify its role in autoimmune disorders, such SLE. In
this sense, the use of an automated flow cytometric method
allowed us to identify eight different merged/calculated
Fig. 3 Frequency of multiple subsets of human PB Th17 cells from NC,
ASLE and ISLE patients, according to the production of IL-2, IL-17,
TNF-α and IFN-γ, after in vitro stimulation with PMA/ionomycin in the
presence of Brefeldin A. Data were analysed by an automated flow
cytometric method based in merging file calculation, using Infinicyt
software. PB peripheral blood, NC healthy individuals, ASLE active
disease, ISLE inactive disease. Statistically significant differences
(p<0.05) when compared: *NC versus ISLE; # ISLE versus ASLE
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Th17 subpopulations from the functional point of view. We
also demonstrated that Th17 cells in peripheral tissues (PB
and LN) produce not only IFN-γ but also TNF-α and/or IL-
2 (Fig. 2). BM Th17 cells showed a distinct profile of
cytokine production, with the majority not secreting the
type 1 cytokines studied. Moreover, a decreased amount of
each cytokine was observed in normal BM as compared to
PB and LN, without significant differences between those
peripheral tissues (data not showed). Although predomi-
nately found in the lung and digestive mucosa, we
demonstrated that Th17 cells can be observed in BM, PB
and lymphoid tissues throughout the body. However, if
Th17 cells represent terminally differentiated cells or
whether they retain plasticity and can develop into another
lineage, such as IL-2, TNF-α and/ or IFNγ secreting Th1
cells, remains unproved.
In our knowledge, this is the first study that compares
the relative distribution and functional activity of Th17 cells
in normal BM, PB and LN according to cytokine
production, and it is also the first application of an
automated flow cytometric method capable of defining
eight different Th17 subpopulations, based on distinct
cytokine expression combinations, after in vitro stimula-
tion. The demonstration of the reliability of this new
statistical approach that may be used for the automated
generation of flow cytometry data files containing infor-
mation on single events about a virtually infinite number of
parameters has already been done by Orfão et al. and opens
the door for all applications of multiparameter flow
cytometry for which a large number of parameters are
needed, provided the fact that the cell population (or cell
populations) of interest could be identified with a relatively
limited number of markers. Thus, by comparing the
expression of four cytokines (IL-2, IL-17, TNF-α and
IFN-γ), we demonstrated that the major Th17 subpopula-
tion in BM only produces IL-17, while in normal peripheral
tissues, this subpopulation was significantly smaller, par-
ticularly in LN. On the other hand, in normal PB, there was
an increase in the Th17 subpopulations producing TNF-α
plus IL-2 and only producing TNF-α, as well as a
significant increase in the subset simultaneously producing
all the four cytokines. In normal LN, this latter subpopu-
lation was found even more represented, alongside the
major Th17 subpopulation producing TNF-α plus IL-2 as
compared to BM (Fig. 2).
Our findings suggest a functional heterogeneity and
plasticity of Th17 cells, which seems to reflect the different
environmental conditions found in the three normal tissues
studied. In fact, Th17 cells retained in the BM appear to
show a reduced ability to produce IL-17 (Table 2), and
almost all do not express the type 1 cytokines studied,
suggesting a protective environment with minimal contact
with antigen and cytokine stimulation, and a strong fidelity
lineage. In contrast, in peripheral tissues, Th17 cells can be
dynamically induced to proliferate and become functional,
activated according to various stimulus and interaction with
antigen-APCs, resulting in a memory or effector phenotype
characterized by an increased ability to co-produce cyto-
kines, particularly in LN where “polyfunctional” Th17 cells
could play an important homeostatic role. Thus, as also
reported by others [24–26], our findings seem to support a
notable flexibility between peripheral Th17 and Th1 cells
or/and a shared early differentiation of Th1 and Th17 cells
from naïve CD4+ T cell. In this sense, as Th1 subsets are
thought to be the crucial player for most of the organ-
specific autoimmune diseases, these peripheral “Th17/Th1”
subpopulations may be involved in the induction of
autoimmunity and inflammatory reactions and represent a
highly pathogenic effector T cell subsets. Thus, once the
functional profile of normal Th17 cells is defined, we focus
our work in their evaluation in a group of SLE patients with
different activity diseases using the automated method
described previously.
In inactive SLE, the Th17 cells producing only TNF-α
were significantly lower than in normal controls. Compared
to controls and active SLE, in inactive disease, there was an
overall increase in the proportion of Th17 subpopulation
co-producing TNF-α/IL-2 with a consequently decrease in
the proportion of Th17 expressing TNF-α alone or IFN-γ/
IL-2 (Fig. 3). Interestingly, alterations in the frequency of
pro-inflammatory cytokine-producing Th17 subpopula-
tions, particularly the increased proportion of Th17 cells
producing TNF-α/IL-2 observed in inactive SLE, might
have important functional implications as these cytokines may
exhibit a potent synergy with IL-17 for pro-inflammatory
effects [27].
In active SLE patients, we found a similar subpopulation
distribution to that observed in normal PB, although
showing a trend towards a higher proportion of Th17 cells
producing IL-17 alone when compared to inactive SLE and
normal controls, reflecting the decrease proportion of Th17
subpopulations expressing TNF-α/IL-2 and TNF-α
(Fig. 3). Actually, in line with the notable cytokine profile
plasticity presented by normal peripheral Th17 cells and
taking into account the enhancement of Th2 cell function
found previously by us in active SLE patients, [28] along
with the miscellaneous immunosuppressive drugs received
by those patients [29, 30], a suppressive effect may be
exerted on Th17 polyfunctional effector phenotype, result-
ing in a decrease proportion of those subpopulations
expressing TNF-α/IL-2 and TNF-α. Especially, those
findings may point to the strong fidelity lineage of Th17
in active disease SLE or even a terminal differentiation
stage related with a repeated antigen challenge as compared
to inactive SLE or normal control groups. Furthermore,
consistent with other human studies [31, 32] that have
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demonstrated a lower number of Th1 cells in active SLE
patients, our data suggest that the cytokine profile of Th17
cells may be essential for synergistically induced Th1-type
cytokines and also potentially be distinct according to the
pro-inflammatory environment. Thus, the local cytokine
milieu may induce new transcription factors and modify
cytokine production even in fully polarized effector T-cell
lineages. The data recorded here provide evidences to show
that, when exposed to certain cytokine milieus, Th17 cells
may acquire the capacity to express not only IL-17 but also
different type 1 cytokines, such as IL-2, TNF-α and IFN-γ,
thus favouring the shifting of these cells toward Th1
phenotype, which is particularly visible in those patients
with inactive disease. In this regard, preliminary data
suggest that these “Th17/Th1” cells appear to be differently
influenced by environmental factors to exhibit dual Th1 and
Th17 functions and to be related with disease activity in
SLE patients, denoting their potential application in clinical
trials as a therapeutic target.
In conclusion, it is conceivable that Th17 cells are
responsive to local cytokine milieus and sufficiently
flexible to acquire the ability to produce type 1 cytokine,
contributing in a pathologic condition to acute and chronic
inflammation mainly in the context of Th1-initiated disease,
herein creating a mixed “Th1/Th17” pathology and reduced
dominance of Th1 in active SLE. Therefore, the data
presented provide a detailed functional characterization of
human Th17 isolated from PB of SLE patients, as well as
from various normal tissues, using a new statistical
approach for the automated generation of flow cytometry
data files that clearly show its great utility in future studies
that would complete the plasticity character of Th17 cells.
In line with this, in the future, it would be important to
determine in a large study, including also non-treated patients,
if these eight T cell subsets, so-called Th1/Th17 cells, can be
considered as distinct and stable lineage of CD4+ T effector
cells that are committed to a certain lineage or whether they
are an intermediate activation state destined to become true
Th1 or Th17 cells and what might be their functional
relevance in the clinical heterogeneity of SLE patients,
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